{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T03:13:32Z","timestamp":1787973212239,"version":"build-2784847793"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"2","funder":[{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"NIDA","doi-asserted-by":"publisher","award":["U01 HL150596-01"],"award-info":[{"award-number":["U01 HL150596-01"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"NIDA","doi-asserted-by":"publisher","award":["RM1 DA055310"],"award-info":[{"award-number":["RM1 DA055310"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Office-based opioid treatment (OBOT) is an evidence-based treatment model for opioid use disorder (OUD) offered by both addiction and general primary care providers (PCPs). Calls exist for more PCPs to offer OBOT. Few studies have been conducted on the primary care characteristics of OBOT patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To characterize medical conditions, medications, and treatment outcomes among patients receiving OBOT with buprenorphine for OUD, and to describe differences among patients by age and by time in care.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This study is a retrospective review of medical records on or before 4\/29\/2019 at an outpatient primary care clinic within a nonprofit addiction treatment setting. Inclusion criterion was all clinic patients actively enrolled in the OBOT program. Patients not prescribed buprenorphine or with no OBOT visits were excluded.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 355 patients, 42.0% had another PCP. Common comorbid conditions included chronic pain and psychiatric diagnosis. Few patients had chronic viral hepatitis or HIV. Patients reported a median of 4 medications. Common medications were cardiovascular, antidepressant, and nonopioid pain agents. Older patients had a higher median number of medications. There was no significant difference in positive opioid urine toxicology (UT) based on age, chronic pain status, or psychoactive medications. Patients retained &amp;gt;1 year were less likely to have positive opioid UT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Clinical needs of many patients receiving OBOT are similar to those of the general population, supporting calls for PCPs to provide OBOT.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/fampra\/cmab166","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T20:21:42Z","timestamp":1638390102000},"page":"234-240","source":"Crossref","is-referenced-by-count":2,"title":["Primary care and medication management characteristics among patients receiving office-based opioid treatment with buprenorphine"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6584-9046","authenticated-orcid":false,"given":"Cindy Xinxin","family":"Du","sequence":"first","affiliation":[{"name":"Yale University School of Medicine, New Haven, CT, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, United States"},{"name":"The APT Foundation Inc., New Haven, CT, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7091-9213","authenticated-orcid":false,"given":"Jeanette M","family":"Tetrault","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, United States"},{"name":"The APT Foundation Inc., New Haven, CT, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn M","family":"Madden","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, United States"},{"name":"The APT Foundation Inc., New Haven, CT, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6697-5220","authenticated-orcid":false,"given":"Declan T","family":"Barry","sequence":"additional","affiliation":[{"name":"The APT Foundation Inc., New Haven, CT, United States"},{"name":"Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"key":"2022032512391551900_CIT0001","volume-title":"Medications for opioid use disorder treatment improvement protocol 63","year":"2018"},{"issue":"10","key":"2022032512391551900_CIT0002","doi-asserted-by":"crossref","first-page":"e0186315","DOI":"10.1371\/journal.pone.0186315","article-title":"Primary care models for treating opioid use disorders: what actually works? A systematic review.","volume":"12","author":"Lagisetty","year":"2017","journal-title":"PLoS One"},{"key":"2022032512391551900_CIT0003","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1097\/QAI.0b013e3182097426","article-title":"The BHIVES collaborative: organization and evaluation of a multisite demonstration of integrated buprenorphine\/naloxone and HIV treatment.","volume":"56","author":"Weiss","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"2022032512391551900_CIT0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMp1802741","article-title":"Primary care and the opioid-overdose crisis\u2014buprenorphine myths and realities.","volume":"379","author":"Wakeman","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"2022032512391551900_CIT0005","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1370\/afm.1595","article-title":"Barriers to primary care physicians prescribing buprenorphine.","volume":"12","author":"Hutchinson","year":"2014","journal-title":"Ann Fam Med"},{"issue":"2","key":"2022032512391551900_CIT0006","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s11606-008-0881-9","article-title":"Integrating buprenorphine treatment into office-based practice: a qualitative study.","volume":"24","year":"2009","journal-title":"J Gen Intern Med"},{"issue":"2","key":"2022032512391551900_CIT0007","doi-asserted-by":"crossref","first-page":"160","DOI":"10.7326\/M19-3975","article-title":"Medication for opioid use disorder: a national survey of primary care physicians.","volume":"173","author":"McGinty","year":"2020","journal-title":"Ann Intern Med"},{"issue":"4","key":"2022032512391551900_CIT0008","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1080\/08897077.2011.599256","article-title":"A case series of buprenorphine\/naloxone treatment in a primary care practice.","volume":"32","author":"Doolittle","year":"2011","journal-title":"Subst Abus"},{"issue":"1","key":"2022032512391551900_CIT0009","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s11524-014-9924-1","article-title":"Buprenorphine maintenance treatment retention improves nationally recommended preventive primary care screenings when integrated into urban federally qualified health centers.","volume":"92","author":"Haddad","year":"2015","journal-title":"J Urban Health"},{"key":"2022032512391551900_CIT0010","first-page":"108619","article-title":"Successful transfer of stable patients on opioid agonist therapies from specialty addiction treatment to primary care settings in Ukraine: a pilot study.","year":"2021","journal-title":"J Subst Abuse Treat"},{"key":"2022032512391551900_CIT0011","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jsat.2015.07.007","article-title":"Engagement and substance dependence in a primary care-based addiction treatment program for people infected with HIV and people at high-risk for HIV infection.","volume":"59","year":"2015","journal-title":"J Subst Abuse Treat"},{"issue":"5\u20136","key":"2022032512391551900_CIT0012","first-page":"444","article-title":"Causes and rates of death among methadone maintenance patients before and after the onset of the HIV\/AIDS epidemic.","volume":"67","author":"Appel","year":"2000","journal-title":"Mt Sinai J Med"},{"key":"2022032512391551900_CIT0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugpo.2016.12.003","article-title":"Causes of death and expected years of life lost among treated opioid-dependent individuals in the United States and Taiwan.","volume":"43","author":"Chang","year":"2017","journal-title":"Int J Drug Policy"},{"key":"2022032512391551900_CIT0014","article-title":"Actual causes of death among patients enrolled in a methadone maintenance program","author":"Tetrault","year":"2013"},{"issue":"1","key":"2022032512391551900_CIT0015","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1186\/s12913-019-4282-z","article-title":"Mortality and causes of death among patients with opioid use disorder receiving opioid agonist treatment: a national register study.","volume":"19","author":"Bech","year":"2019","journal-title":"BMC Health Serv Res"},{"key":"2022032512391551900_CIT0016","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.drugalcdep.2017.10.007","article-title":"Treatment for opioid use and outcomes in older adults: a systematic literature review.","volume":"182","author":"Carew","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"2022032512391551900_CIT0017","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.02.030","article-title":"Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study.","volume":"150","year":"2015","journal-title":"Drug Alcohol Depend"},{"key":"2022032512391551900_CIT0018","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jsat.2016.12.010","article-title":"Long-term retention in office based opioid treatment with buprenorphine.","volume":"74","year":"2017","journal-title":"J Subst Abuse Treat"},{"key":"2022032512391551900_CIT0019","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.drugalcdep.2016.10.039","article-title":"Psychoactive medications and disengagement from office based opioid treatment (OBOT) with buprenorphine.","volume":"170","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"2022032512391551900_CIT0020","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","article-title":"What is polypharmacy? A systematic review of definitions.","volume":"17","author":"Masnoon","year":"2017","journal-title":"BMC Geriatr"},{"key":"2022032512391551900_CIT0021"},{"key":"2022032512391551900_CIT0022","volume-title":"MASS package for R 7.3-54","author":"Ripley","year":"2021"},{"issue":"2","key":"2022032512391551900_CIT0023","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/apc.2013.0179","article-title":"Patient perspectives of an integrated program of medical care and substance use treatment.","volume":"28","author":"Drainoni","year":"2014","journal-title":"AIDS Patient Care STDS"},{"key":"2022032512391551900_CIT0024","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2147\/SAR.S12944","article-title":"Intersection of chronic pain treatment and opioid analgesic misuse: causes, treatments, and policy strategies.","volume":"2","author":"Wachholtz","year":"2011","journal-title":"Subst Abuse Rehabil"},{"issue":"1\u20133","key":"2022032512391551900_CIT0025","first-page":"243","article-title":"Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine\/naloxone treatment.","volume":"127","year":"2013","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"2022032512391551900_CIT0026","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jacc.2020.11.002","article-title":"Cardiovascular complications of opioid use.","volume":"77","author":"Krantz Mori","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"2022032512391551900_CIT0027","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1001\/jama.2015.13766","article-title":"Trends in prescription drug use among adults in the United States from 1999\u20132012.","volume":"314","author":"Kantor","year":"2015","journal-title":"JAMA"},{"key":"2022032512391551900_CIT0028","volume-title":"Estimate for the population of Connecticut by age group, sex, race, and Hispanic ethnicity: July 1, 2018","year":"2018"},{"issue":"3","key":"2022032512391551900_CIT0029","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jsat.2005.01.007","article-title":"Characteristics of older opioid maintenance patients.","volume":"28","author":"Lofwall","year":"2005","journal-title":"J Subst Abuse Treat"},{"issue":"5","key":"2022032512391551900_CIT0030","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/00019442-200409000-00015","article-title":"Characteristics and treatment outcome of older methadone-maintenance patients.","volume":"12","author":"Firoz","year":"2004","journal-title":"Am J Geriatr Psychiatry"},{"issue":"6","key":"2022032512391551900_CIT0031","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s10865-004-0005-x","article-title":"Health conditions among aging narcotics addicts: medical examination results.","volume":"27","author":"Hser","year":"2004","journal-title":"J Behav Med"},{"issue":"6","key":"2022032512391551900_CIT0032","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/JGP.0b013e31816ff35a","article-title":"The prevalence of mental and physical health disorders among older methadone patients.","volume":"16","author":"Rosen","year":"2008","journal-title":"Am J Geriatr Psychiatry"},{"issue":"2","key":"2022032512391551900_CIT0033","first-page":"126","article-title":"Does psychiatric comorbidity affect drug abuse treatment outcome? A prospective assessment of drug abuse, treatment tenure and infectious diseases in an Israeli methadone maintenance clinic.","volume":"43","author":"Gelkopf","year":"2006","journal-title":"Isr J Psychiatry Relat Sci"}],"container-title":["Family Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/fampra\/article-pdf\/39\/2\/234\/43019805\/cmab166.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/fampra\/article-pdf\/39\/2\/234\/43019805\/cmab166.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T18:52:06Z","timestamp":1648234326000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/fampra\/article\/39\/2\/234\/6459271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,12,10]]},"published-print":{"date-parts":[[2022,3,24]]}},"URL":"https:\/\/doi.org\/10.1093\/fampra\/cmab166","relation":{},"ISSN":["1460-2229"],"issn-type":[{"value":"1460-2229","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4,1]]},"published":{"date-parts":[[2021,12,10]]}}}